Drug Profile


Alternative Names: 6,6,7-COUMATE; BN 83495; Irostustat; oristusane; STX 64PC; STX-64

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen
  • Developer Ipsen; Peter MacCallum Cancer Centre
  • Class Antineoplastics; Sulfonic acids
  • Mechanism of Action Steryl sulfatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Breast cancer; Endometrial cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 11 Mar 2016 Discontinued - Phase-II for Breast cancer (Neoadjuvant therapy) in United Kingdom (PO)
  • 11 Mar 2016 Ipsen terminates phase II trial in Breast cancer (Neoadjuvant therapy) in United Kingdom (NCT01662726)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top